Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy

NCT07642635 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

DRUG: Semaglutide (Rybelsus®)
OTHER: Placebo

Sponsor

Vanderbilt University Medical Center